Valneva has received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its Covid-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the company is in breach of its obligations under the Supply Agreement, which the company denies.
Valneva is continuing its VLA2001 development plan. Testing for the company’s Phase III trial, Cov-Compare, is ongoing at Public Health England (PHE). Valneva recently announced that its Phase III results are expected to be available early in the fourth quarter and that these results will form part of its rolling submission for conditional approval of VLA2001 with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Subject to these data and MHRA approval, Valneva believes that initial approval for VLA2001 could be granted in late 2021.
Valneva has re-affirmed its commitment to the development of VLA2001 and intends to increase its efforts with other potential customers to ensure that its inactivated vaccine can be used in the fight against the Covid-19 pandemic.
Image credit: Daniel Schludi